Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan, … , Esteban Celis, Dmitry I. Gabrilovich
Rupal Ramakrishnan, … , Esteban Celis, Dmitry I. Gabrilovich
Published March 15, 2010
Citation Information: J Clin Invest. 2010;120(4):1111-1124. https://doi.org/10.1172/JCI40269.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 12

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

  • Text
  • PDF
Abstract

Cancer immunotherapy faces a serious challenge because of low clinical efficacy. Recently, a number of clinical studies have reported the serendipitous finding of high rates of objective clinical response when cancer vaccines are combined with chemotherapy in patients with different types of cancers. However, the mechanism of this phenomenon remains unclear. Here, we tested in mice several cancer vaccines and an adoptive T cell transfer approach to cancer immunotherapy in combination with several widely used chemotherapeutic drugs. We found that chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTLs through a dramatic perforin-independent increase in permeability to GrzB released by the CTLs. This effect was mediated via upregulation of mannose-6-phosphate receptors on the surface of tumor cells and was observed in mouse and human cells. When combined with chemotherapy, CTLs raised against specific antigens were able to induce apoptosis in neighboring tumor cells that did not express those antigens. These data suggest that small numbers of CTLs could mediate a potent antitumor effect when combined with chemotherapy. In addition, these results provide a strong rationale for combining these modalities for the treatment of patients with advanced cancers.

Authors

Rupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj, Terri Hunter, Hyun-Il Cho, Scott Antonia, Soner Altiok, Esteban Celis, Dmitry I. Gabrilovich

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Total
Citations: 3 10 16 16 23 11 15 11 8 18 16 13 22 14 20 12 1 229
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (229)

Title and authors Publication Year
Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines
Zheng Q, He M, Mao Z, Huang Y, Li X, Long L, Guo M, Zou D
Vaccines 2025
Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review
Lv X, Zhang PB, Zhang EL, Yang S
World Journal of Surgical Oncology 2025
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma
Deng W, Xie J, Wang T, Luo L, Zhu G, Xiao Y, Tao J, Lin L, Ge X, Wen W, Wang M, Yu B, Liu Y, Luo R, Wan R, Hu Z, Shan R
BMC Cancer 2025
Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H, Tan SC
Molecular Biology Reports 2024
Immunotherapy for the treatment of biliary tract cancer: an evolving landscape
Wilbur HC, Azad NS
Therapeutic advances in medical oncology 2024
WT1 Cancer Vaccine in Advanced Pancreatic Cancer: A Systematic Review
Gugulothu KN, Anvesh Sai P, Suraparaju S, Karuturi SP, Pendli G, Kamma RB, Nimmagadda K, Modepalli A, Mamilla M, Vashist S
Cureus 2024
Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study
Choi CH, Lee JW, Bae DS, Kang ES, Cho D, Kim YM, Kim K, Kim JW, Kim HS, Kim YT, Lee JY, Lim MC, Oh T, Song B, Jeon I, Park M, Kim WH, Kang CY, Kim BG
Frontiers in immunology 2024
Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers
Ding K, Peng Z, Xu Y
Therapeutic advances in medical oncology 2024
Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials
Thompson R, Cao X
Frontiers in immunology 2024
Metronomic chemotherapy in cancer treatment: new wine in an old bottle
Wu HL, Zhou HX, Chen LM, Wang SS
Theranostics 2024
Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs
Pan F, Liu J, Chen Y, Zhu B, Chen W, Yang Y, Zhu C, Zhao H, Liu X, Xu Y, Xu X, Huo L, Xie L, Wang R, Gu J, Huang G
Scientific Reports 2024
Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies.
Looi CK, Loo EM, Lim HC, Chew YL, Chin KY, Cheah SC, Goh BH, Mai CW
Frontiers in immunology 2024
Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders.
Li X, Liu Y, Gui J, Gan L, Xue J
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2024
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK
Breast Cancer Research and Treatment 2023
Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review
Lei Y, Lin L, Cheng S, Shao Q, Ding C, Zuo R, Chen W, Liao Q, Liu G
Frontiers in Oncology 2023
Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
Muraro E, Vinante L, Fratta E, Bearz A, Höfler D, Steffan A, Baboci L
Cancers 2023
Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1.
Wang RN, Yu Q, Wang XB, Zhu D, Li GL, Li ZX, Jiang W, Li W, Dang YJ
Acta Pharmacologica Sinica 2023
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J, Han Y, Hu Y, Feng X, Meng X, Guo S, Sun C, Chen G, Li K
BMJ Open 2023
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Martínez-Pérez A, Rodrigo JP, García-Pedrero JM, Gonzalez S
Cancers 2023
Editorial: Current concepts of cellular and biological drugs to modulate regulatory T cell activity in the clinic, volume II
Wenger V, Zeiser R
Frontiers in immunology 2023
Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
Guo Y, Jia J, Hao Z, Yang J
Frontiers in pharmacology 2023
Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
Gao Z, Huang S, Wang S, Tang D, Xu W, Zeng R, Qiao G
2023
Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells
Yurt F, Özel D, Tunçel A, Gokbayrak O, Aktas S
ACS Omega 2023
The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
Liang S, Wang H, Tian H, Xu Z, Wu M, Hua D, Li C
Frontiers in immunology 2023
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care
Xiao Y, Li ZZ, Zhong NN, Cao LM, Liu B, Bu LL
Translational oncology 2023
Intensified NK cell therapy in combination with low-dose chemoradiotherapy against human colorectal cancer.
Nguyen HPQ, Bae WK, Park MS, Chung IJ, Nam TK, Jeong JU, Uong TNT, Cho D, Kim SK, Yoon M
Cancer Immunology, Immunotherapy 2023
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma
Ding Y, Wang S, Qiu Z, Zhu C, Wang Y, Zhao S, Qiu W, Wang K, Lv J, Qi W
Frontiers in immunology 2023
The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies
Rahimi A, Malakoutikhah Z, Rahimmanesh I, Ferns GA, Nedaeinia R, Ishaghi SM, Dana N, Haghjooy Javanmard S
Cancer Cell International 2023
Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy
Zhao F, Zhao C, Xu T, Lan Y, Lin H, Wu X, Li X
Frontiers in immunology 2023
Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma
Y Gan, G Li, X Ou, C Wang, Q Du
Frontiers in Oncology 2022
Emerging mechanisms of immunotherapy resistance in sarcomas.
Florou V, Wilky BA
2022
Nanodrugs Targeting T Cells in Tumor Therapy
Haist M, Mailänder V, Bros M
Frontiers in immunology 2022
Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review.
Li N, Xu T, Zhou Z, Li P, Jia G, Li X
Frontiers in Oncology 2022
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
Principe N, Aston WJ, Hope DE, Tilsed CM, Fisher SA, Boon L, Dick IM, Chin WL, McDonnell AM, Nowak AK, Lake RA, Chee J, Lesterhuis WJ
Frontiers in immunology 2022
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
Dongye Z, Li J, Wu Y
British Journal of Cancer 2022
A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma
Ahmed S, Mobashir M, Al-Keridis LA, Alshammari N, Adnan M, Abid M, Hassan MI
Frontiers in Oncology 2022
Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
Zhang L, Zhou C, Zhang S, Chen X, Liu J, Xu F, Liang W
Frontiers in Oncology 2022
Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation
Fabian KP, Kowalczyk JT, Reynolds ST, Hodge JW
Cells 2022
Construction of an immunogenic cell death-based risk score prognosis model in breast cancer
Li Y, Feng J, Wang T, Li M, Zhang H, Rong Z, Cheng W, Duan Y, Chen Z, Hu A, Yu T, Zhang J, Shang Y, Zou Y, Ma F, Guo B
Frontiers in Genetics 2022
Immune-based combination therapy for esophageal cancer.
Wang H, Xu Y, Zuo F, Liu J, Yang J
Frontiers in immunology 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE
Journal of Clinical Oncology 2022
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H
Clinical cancer research 2022
Chemotherapy: A partnership with immunotherapy in non‐small cell lung cancer
Mendes AS, Romão R, Febra J, Azevedo SX, Fidalgo P, Araújo A
Thoracic Cancer 2022
Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review
Alhamhoom Y, Kakinani G, Rahamathulla M, Ali M. Osmani R, Hani U, Yoonus Thajudeen K, Kiran Raj G, Gowda DV
2022
Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator
Xiao Q, Li X, Liu C, Jiang Y, He Y, Zhang W, Azevedo HS, Wu W, Xia Y, He W
Acta pharmaceutica Sinica. B 2022
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas
LS Lamb, L Pereboeva, S Youngblood, GY Gillespie, LB Nabors, JM Markert, A Dasgupta, C Langford, HT Spencer
Scientific Reports 2021
NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma
C Garofalo, CD Marco, CM Cristiani
Frontiers in Oncology 2021
Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives
R Bagherifar, SH Kiaie, Z Hatami, A Ahmadi, A Sadeghnejad, B Baradaran, R Jafari, Y Javadzadeh
Journal of nanobiotechnology 2021
The Immunology of Hormone Receptor Positive Breast Cancer
J Goldberg, RG Pastorello, T Vallius, J Davis, YX Cui, J Agudo, AG Waks, T Keenan, SS McAllister, SM Tolaney, EA Mittendorf, JL Guerriero
Frontiers in immunology 2021
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
RJ Harris, A Cheung, JC Ng, R Laddach, AM Chenoweth, S Crescioli, M Fittall, D Dominguez-Rodriguez, J Roberts, D Levi, F Liu, E Alberts, J Quist, A Santaolalla, SE Pinder, C Gillett, N Hammar, S Irshad, MV Hemelrijck, DK Dunn-Walters, F Fraternali, JF Spicer, KE Lacy, S Tsoka, A Grigoriadis, AN Tutt, SN Karagiannis
Cancer research 2021
Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
F Tarantini, C Cumbo, L Anelli, A Zagaria, G Specchia, P Musto, F Albano
Cancers 2021
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment
KP Fabian, B Wolfson, JW Hodge
Frontiers in Oncology 2021
Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study
L Ke, L Wang, J Yu, X Meng
Frontiers in Oncology 2021
Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine
GN Shi, M Hu, C Chen, J Fu, S Shao, Y Zhou, L Wu, T Zhang
Therapeutic advances in medical oncology 2021
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
D Morgensztern, MC Dols, SP Aix, PE Postmus, J Bennouna, JR Fischer, O Juan-Vidal, DJ Stewart, A Ardizzoni, R Bhore, M Wolfsteiner, M Reck, D Talbot, R Govindan, TJ Ong
Frontiers in Oncology 2021
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer
W Liu, Y Wang, Y Xie, T Dai, M Fan, C Li, Y Zou
Cell Death Discovery 2021
A Miniaturized Platform for Multiplexed Drug Response Imaging in Live Tumors
S Bhagavatula, D Thompson, SW Ahn, K Upadhyaya, A Lammers, K Deans, C Dominas, B Ferland, V Valvo, G Liu, O Jonas
Cancers 2021
Targeting the DNA damage response in immuno-oncology: developments and opportunities
RM Chabanon, M Rouanne, C J., JC Soria, P Pasero, S Postel-Vinay
Nature Reviews Cancer 2021
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
KP Fabian, MR Padget, R Fujii, J Schlom, JW Hodge
Journal for ImmunoTherapy of Cancer 2021
Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies
NT Truong, T Gargett, MP Brown, LM Ebert
Cancers 2021
Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
Y Chen, Y Wang, Z Yang, M Hu, Y Zhang, F Qian, W Zhang, B Zhang, B Han
Frontiers in Oncology 2021
Current status of conversion surgery for stage IV gastric cancer
J Kinoshita, T Yamaguchi, H Moriyama, S Fushida
Surgery Today 2021
Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
M Niu, SE Combs, A Linge, M Krause, M Baumann, F Lohaus, N Ebert, I Tinhofer, V Budach, J von der Grün, F Rödel, AL Grosu, G Multhoff
Radiation Oncology 2021
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC
PO Gaudreau, MV Negrao, KG Mitchell, A Reuben, EM Corsini, J Li, TV Karpinets, Q Wang, L Diao, J Wang, L Federico, ER Parra-Cuentas, R Khairullah, C Behrens, AM Correa, D Gomez, L Little, C Gumbs, HN Kadara, J Fujimoto, DJ McGrail, AA Vaporciyan, SG Swisher, G Walsh, MB Antonoff, A Weissferdt, H Tran, E Roarty, C Haymaker, C Bernatchez, J Zhang, PA Futreal, II Wistuba, T Cascone, JV Heymach, B Sepesi, J Zhang, DL Gibbons
Journal of Thoracic Oncology 2021
Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor-Associated Antigen Vaccine and Chemotherapeutic Regimens
CY Huang, SY Lin, TA Hsu, HP Hsieh, MH Huang
Nanomaterials 2021
Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer
R Kim, T Kin
Cancers 2021
Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer
T Bos, J Ratti, H Harada
2021
A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.
Zhang F, Zhang J, Zhao L, Zhai M, Zhang T, Yu D
Frontiers in immunology 2021
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
Z Gu, CD Silva, KV der Maaden, F Ossendorp, L Cruz
Pharmaceutics 2020
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
O Brück, O Dufva, H Hohtari, S Blom, R Turkki, M Ilander, P Kovanen, C Pallaud, PM Ramos, H Lähteenmäki, K Välimäki, ME Missiry, A Ribeiro, O Kallioniemi, K Porkka, T Pellinen, S Mustjoki
Blood Advances 2020
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
O Yeku, AL Russo, H Lee, D Spriggs
Journal of Translational Medicine 2020
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
W Mu, Q Chu, Y Liu, N Zhang
Nano-Micro Letters 2020
The rediscovery of platinum-based cancer therapy
S Rottenberg, C Disler, P Perego
Nature Reviews Cancer 2020
CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies
AM Melo, MJ Conroy, EK Foley, É Dockry, EP Breen, JV Reynolds, J Lysaght, DG Doherty
Cancer Immunology, Immunotherapy 2020
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series
R Tamura, Y Morimoto, K Kosugi, M Sato, Y Oishi, R Ueda, R Kikuchi, H Nagashima, T Hikichi, S Noji, Y Kawakami, H Sasaki, K Yoshida, M Toda
BMC Cancer 2020
Recent Developments of Systemic Chemotherapy for Gastric Cancer
H Arai, TE Nakajima
Cancers 2020
Immunogenic chemotherapy in two mouse colon cancer models
T Taniura, Y Iida, H Kotani, K Ishitobi, Y Tajima, M Harada
Cancer Science 2020
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy
Y Qin, L Jiang, M Yu, Y Li, X Zhou, Y Wang, Y Gong, F Peng, J Zhu, Y Liu, Y Xu, L Zhou, Y Lu, M Huang
Scientific Reports 2020
Clinical Data on Immunotherapy in Breast Cancer
JC Radosa, L Stotz, C Müller, AC Kaya, EF Solomayer, MP Radosa
Breast Care 2020
BRAF targeting sensitizes resistant melanoma to cytotoxic T cells
C Atay, T Kwak, S Lavilla-Alonso, L Donthireddy, AD Richards, VE Moberg, S Pilon-Thomas, MJ Schell, JL Messina, VW Rebecca, M Xiao, J Tan, G Zhang, JS Weber, M Herlyn, AA Sarnaik, DI Gabrilovich
Clinical cancer research 2019
Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients
Z Yuhan, W Shuaibing, Y Beibei, L Su, D Yiyi, L Hong
Cancer biology & medicine 2019
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression
Y Cao, J Trillo-Tinoco, RA Sierra, C Anadon, W Dai, E Mohamed, L Cen, TL Costich, A Magliocco, D Marchion, R Klar, S Michel, F Jaschinski, RR Reich, S Mehrotra, JR Cubillos-Ruiz, DH Munn, JR Conejo-Garcia, PC Rodriguez
Nature Communications 2019
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer
C Wang, P Kulkarni, R Salgia
Molecular Therapy — Oncolytics 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
YJ Bang, YK Kang, DV Catenacci, K Muro, CS Fuchs, R Geva, H Hara, T Golan, M Garrido, SI Jalal, C Borg, T Doi, HH Yoon, MJ Savage, J Wang, RP Dalal, S Shah, ZA Wainberg, HC Chung
Gastric Cancer 2019
Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
JT Zoine, KA Knight, LC Fleischer, KS Sutton, KC Goldsmith, CB Doering, HT Spencer
OncoImmunology 2019
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
S Miyauchi, SS Kim, J Pang, KA Gold, JS Gutkind, JA Califano, LK Mell, EE Cohen, AB Sharabi
Clinical cancer research 2019
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade
BR Heath, NL Michmerhuizen, CR Donnelly, K Sansanaphongpricha, D Sun, JC Brenner, YL Lei
Journal of dental research 2019
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Y Xu, B Wan, , P Zhan, Y Zhao, T Zhang, H Liu, MZ Afzal, S Dermime, SN Hochwald, P Hofman, H Borghaei, D Lin, T Lv, Y Song
Translational Lung Cancer Research 2019
Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
WJ Aston, DE Hope, AM Cook, L Boon, I Dick, AK Nowak, RA Lake, WJ Lesterhuis
OncoImmunology 2019
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia
D Ocadlikova, M Lecciso, A Isidori, F Loscocco, G Visani, S Amadori, M Cavo, A Curti
Frontiers in Oncology 2019
Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
M Zhang, K Liu, M Wang
RSC Advances 2019
Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C high Myeloid Cells
C Wu, X Tan, X Hu, M Zhou, J Yan, C Ding
Journal of immunology (Baltimore, Md. : 1950) 2019
The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma
LY de Almeida, FS Mariano, DC Bastos, KA Cavassani, J Raphelson, VS Mariano, M Agostini, FS Moreira, RD Coletta, RO Mattos-Graner, E Graner
Cancer Chemotherapy and Pharmacology 2019
The Future of Mesothelioma Research: Basic Science Research
Fear VS, Cook AM, Fisher SA
2019
Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine
X Hong, T Dong, T Yi, J Hu, Z Zhang, S Lin, W Niu
Chinese Journal of Cancer Research 2018
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
M Efremova, D Rieder, V Klepsch, P Charoentong, F Finotello, H Hackl, N Hermann-Kleiter, M Löwer, G Baier, A Krogsdam, Z Trajanoski
Nature Communications 2018
Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
A Sherif, M Winerdal, O Winqvist
Bladder Cancer 2018
Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer
M Li, Y Wang, F Wei, X An, N Zhang, S Cao, B Ren, X Zhang, X Ren
Journal of Breast Cancer 2018
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma
S Chakrabarti, H Dong, HR Paripati, HJ Ross, HH Yoon
The oncologist 2018
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
T Poggio, J Duyster, A Illert
Cancers 2018
Cyclophosphamide eradicates murine immunogenic tumor coding for a non-self-antigen and induces antitumor immunity
ML Salem, SA El-Naggar, HA Mahmoud, RM Elgharabawy, AM Bader
International journal of immunopathology and pharmacology 2018
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
C Grasselly, M Denis, A Bourguignon, N Talhi, D Mathe, A Tourette, L Serre, LP Jordheim, EL Matera, C Dumontet
Frontiers in immunology 2018
Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
W Lin, M Chen, L Hong, H Zhao, Q Chen
Frontiers in Oncology 2018
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
S Xu, F Cui, D Huang, D Zhang, A Zhu, X Sun, Y Cao, S Ding, Y Wang, E Gao, F Zhang
International Journal of Nanomedicine 2018
Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
K Shen, J Cui, Y Wei, X Chen, G Liu, X Gao, W Li, H Lu, P Zhan, T Lv, D Lin
Journal of Thoracic Disease 2018
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy
H Zheng, M Zeltsman, MG Zauderer, T Eguchi, RG Vaghjiani, PS Adusumilli
Immunotherapy 2017
The Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune response
MH Chuang, MS Jan, JT Chang, FJ Lu
BMC complementary and alternative medicine 2017
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model
S Hori, M Miyake, Y Tatsumi, S Onishi, Y Morizawa, Y Nakai, N Tanaka, K Fujimoto, A Ahmad
PloS one 2017
Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in?vitro study
M Nishio-Nagai, S Suzuki, K Yoshikawa, R Ueda, Y Kazaoka
International journal of oncology 2017
Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression
R Deng, FY Fan, H Yi, L Fu, Y Zeng, Y Wang, XJ Miao, YR Shuai, GC He, Y Su
Experimental and therapeutic medicine 2017
Trichosanthin increases Granzyme B penetration into tumor cells by upregulation of CI-MPR on the cell surface
C Li, M Zeng, H Chi, J Shen, TB Ng, G Jin, D Lu, X Fan, B Xiong, Z Xiao, O Sha
Oncotarget 2017
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely
D Day, AM Monjazeb, E Sharon, SP Ivy, EH Rubin, GL Rosner, MO Butler
Clinical cancer research 2017
Efficacy of granulocyte-macrophage colony-stimulating factor combined with metronomic paclitaxel in the treatment of Lewis lung carcinoma transplanted in mice
N Zhu, R Qin, Q Zhang, S Fu, S Liu, Y Chen, J Fan, Y Han
Oncotarget 2017
The Growth Inhibitory Potential and Antimetastatic Effect of Camel Urine on Breast Cancer Cells In Vitro and In Vivo
F Romli, N Abu, FA Khorshid, SU Najmuddin, YS Keong, NE Mohamad, M Hamid, NB Alitheen, NM Rahman
Integrative Cancer Therapies 2016
Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3
WA Chang, JY Hung, SF Jian, YS Lin, CY Wu, YL Hsu, PL Kuo
Oncotarget 2016
Vaccines for established cancer: overcoming the challenges posed by immune evasion
SH van der Burg, R Arens, F Ossendorp, T Hall, CJ Melief
Nature Reviews Cancer 2016
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
H Zheng, W Zhao, C Yan, CC Watson, M Massengill, M Xie, C Massengill, DR Noyes, GV Martinez, R Afzal, Z Chen, X Ren, SJ Antonia, EB Haura, B Ruffell, AA Beg
Clinical cancer research 2016
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
L Bialkowski, A Weijnen, KV der Jeught, D Renmans, L Daszkiewicz, C Heirman, G Stangé, K Breckpot, JL Aerts, K Thielemans
Scientific Reports 2016
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy
H Takahashi, K Sakakura, I Mito, S Ida, K Chikamatsu
Cancer Science 2016
Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals
L Shi, H Lin, G Li, Y Sun, J Shen, J Xu, C Lin, S Yeh, X Cai, C Chang
Cancer Letters 2016
Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma
NB Roberts, AS Wadajkar, JA Winkles, E Davila, AJ Kim, GF Woodworth
OncoImmunology 2016
Chemotherapy remains an essential element of personalized care for persons with lung cancers
MD Hellmann, BT Li, JE Chaft, MG Kris
Annals of Oncology 2016
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
W Ma, BM Gilligan, J Yuan, T Li
Journal of Hematology & Oncology 2016
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
H Pandha, G Simpson, K Relph, A Melcher, K Harrington
Oncolytic Virotherapy 2016
Targeting Androgen Receptor (AR)->IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression
L Shi, H Lin, G Li, RA Jin, J Xu, Y Sun, WL Ma, S Yeh, X Cai, C Chang
Molecular cancer therapeutics 2016
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
SA Funt, JE Rosenberg
Nature Reviews Clinical Oncology 2016
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
EC Martino, G Misso, P Pastina, S Costantini, F Vanni, C Gandolfo, C Botta, F Capone, A Lombardi, L Pirtoli, P Tassone, C Ulivieri, P Tagliaferri, MG Cusi, M Caraglia, P Correale
Cell Death Discovery 2016
Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists
SZ Manrique, AL Dominguez, N Mirza, CD Spencer, JM Bradley, JH Finke, JJ Lee, LR Pease, SJ Gendler, PA Cohen
Oncotarget 2016
Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy
HD Han, Y Byeon, TH Kang, ID Jung, JW Lee, BC Shin, YJ Lee, AK Sood, YM Park
International Journal of Nanomedicine 2016
Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies
M Janakiram, V Pareek, H Cheng, DM Narasimhulu, X Zang
Immunotherapy 2016
Combination approaches in NSCLC involving immune checkpoint inhibitors
S Arulananda, G Rivalland, T John
Lung Cancer Management 2016
CAR T-cell immunotherapy: The path from the by-road to the freeway?
LM Whilding, J Maher
Molecular Oncology 2015
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
H Dai, W Zhang, X Li, Q Han, Y Guo, Y Zhang, Y Wang, C Wang, F Shi, Y Zhang, M Chen, K Feng, Q Wang, H Zhu, X Fu, S Li, W Han
OncoImmunology 2015
Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6
G Cao, J Wang, X Zheng, H Wei, Z Tian, R Sun
The Journal of biological chemistry 2015
Dab2 , a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy
MS Ahmed, SE Byeon, Y Jeong, MA Miah, M Salahuddin, Y Lee, SS Park, YS Bae
OncoImmunology 2015
Immunotherapy in lung cancer
Liza C Villaruz, Aparna Kalyan, Hassane Zarour, Mark A Socinski
Translational Lung Cancer Research 2015
Emerging immunotherapies for bladder cancer:
JW Kim, Y Tomita, J Trepel, AB Apolo
Current Opinion in Oncology 2015
Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2
YL Kuo, CH Chen, TH Chuang, WK Hua, WJ Lin, WH Hsu, PM Chang, SL Hsu, TH Huang, CY Kao, CY Huang
Evidence-Based Complementary and Alternative Medicine 2015
Photodynamic Therapy-mediated Cancer Vaccination Enhances Stem-like Phenotype and Immune Escape, Which Can Be Blocked by Thrombospondin-1 Signaling through CD47 Receptor Protein
Y Zheng, F Zou, J Wang, G Yin, V Le, Z Fei, J Liu
The Journal of biological chemistry 2015
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
EJ Wyluda, J Cheng, TD Schell, JS Haley, C Mallon, RI Neves, G Robertson, J Sivik, H Mackley, G Talamo, JJ Drabick
Cancer biology & therapy 2015
Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy
DA Spencer, JS Young, D Kanojia, JW Kim, SP Polster, JP Murphy, MS Lesniak
Therapeutic Delivery 2015
Development of PROSTVAC immunotherapy in prostate cancer
P Singh, SK Pal, A Alex, N Agarwal
Future Oncology 2015
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
K Kersten, C Salvagno, KE de Visser
Frontiers in immunology 2015
Peptide-Based Treatment: A Promising Cancer Therapy
YF Xiao, MM Jie, BS Li, CJ Hu, R Xie, B Tang, SM Yang
Journal of Immunology Research 2015
Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
MJ McCoy, C Hemmings, TJ Miller, SJ Austin, MK Bulsara, N Zeps, AK Nowak, RA Lake, CF Platell
British Journal of Cancer 2015
Pancreatic Cancer: Progress in Systemic Therapy
L Perkhofer, TJ Ettrich, T Seufferlein
Gastrointestinal Tumors 2015
Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice
Hsu FT, Chen TC, Chuang HY, Chang YF, Hwang JJ
Oncotarget 2015
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy
DS Chung, HJ Shin, YK Hong
Journal of Immunology Research 2014
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance
RM Vielnascher, E Hainzl, NR Leitner, M Rammerstorfer, D Popp, A Witalisz, R Rom, M Karaghiosoff, T Kolbe, S Müller, T Rülicke, C Lassnig, B Strobl, M Müller
Transgenic Research 2014
Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
HY Chuang, YF Chang, RS Liu, JJ Hwang, RA Veitia
PloS one 2014
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice
S Kim, R Ramakrishnan, S Lavilla-Alonso, P Chinnaiyan, N Rao, E Fowler, J Heine, DI Gabrilovich
Cancer Immunology, Immunotherapy 2014
Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer
M Arlen, P Arlen, G Coppa, J Crawford, XP Wang, O Saric, A Dubeykovskiy, E Molmenti
World journal of gastrointestinal oncology 2014
Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene
M Yoshimura, Y Tada, K Ofuzi, M Yamamoto, T Nakatsura
Oncology reports 2014
CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors
J Hu, S Zhu, X Xia, L Zhang, ES Kleinerman, S Li
Molecular Cancer 2014
Immunotherapy for Lung Cancer: Has it Finally Arrived?
AA Mostafa, DG Morris
Frontiers in Oncology 2014
Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer:
S Nishida, S Koido, Y Takeda, S Homma, H Komita, A Takahara, S Morita, T Ito, S Morimoto, K Hara, A Tsuboi, Y Oka, S Yanagisawa, Y Toyama, M Ikegami, T Kitagawa, H Eguchi, H Wada, H Nagano, J Nakata, Y Nakae, N Hosen, Y Oji, T Tanaka, I Kawase, A Kumanogoh, J Sakamoto, Y Doki, M Mori, T Ohkusa, H Tajiri, H Sugiyama
Journal of immunotherapy (Hagerstown, Md. : 1997) 2014
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
K Odunsi, J Matsuzaki, SR James, P Mhawech-Fauceglia, T Tsuji, A Miller, W Zhang, SN Akers, EA Griffiths, A Miliotto, A Beck, CA Batt, G Ritter, S Lele, S Gnjatic, AR Karpf
Cancer immunology research 2014
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
AR de Biasi, J Villena-Vargas, PS Adusumilli
Clinical cancer research 2014
Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
J Chu, S He, Y Deng, J Zhang, Y Peng, T Hughes, L Yi, CH Kwon, QE Wang, SM Devine, X He, XF Bai, CC Hofmeister, J Yu
Clinical cancer research 2014
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RA
Oncotarget 2014
Profound impairment of adaptive immune responses by alkylating chemotherapy
AJ Litterman, DM Zellmer, KL Grinnen, MA Hunt, AZ Dudek, AM Salazar, JR Ohlfest
Journal of immunology (Baltimore, Md. : 1950) 2013
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
C Zielinski, S Knapp, C Mascaux, F Hirsch
Annals of Oncology 2013
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L Bracci, G Schiavoni, A Sistigu, F Belardelli
Cell Death and Differentiation 2013
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
V Lavoué, A Thédrez, J Levêque, F Foucher, S Henno, V Jauffret, MA Belaud-Rotureau, V Catros, F Cabillic
Journal of Translational Medicine 2013
Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination
A Litterman, A Dudek, DA Largaespada
OncoImmunology 2013
The immune system and inflammation in breast cancer
X Jiang, DJ Shapiro
Molecular and Cellular Endocrinology 2013
Chemoimmunotherapy: reengineering tumor immunity
G Chen, LA Emens
Cancer Immunology, Immunotherapy 2013
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
T Ghansah, N Vohra, K Kinney, A Weber, K Kodumudi, G Springett, AA Sarnaik, S Pilon-Thomas
Cancer Immunology, Immunotherapy 2013
Exploiting ecological principles to better understand cancer progression and treatment
D Basanta, AR Anderson
Interface Focus 2013
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
M Jure-Kunkel, G Masters, E Girit, G Dito, F Lee, JT Hunt, R Humphrey
Cancer Immunology, Immunotherapy 2013
Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells
KL Yang, YS Wang, CC Chang, SC Huang, YC Huang, MS Chi, KH Chi
PloS one 2013
Immunological off-target effects of standard treatments in gastrointestinal cancers
AG Duffy, TF Greten
Annals of Oncology 2013
Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response
F Milano, L Mari, W de Luijtgaarden, K Parikh, S Calpe, KK Krishnadath
Frontiers in Oncology 2013
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
WJ Lesterhuis, J Salmons, AK Nowak, EN Rozali, A Khong, IM Dick, JA Harken, BW Robinson, RA Lake
PloS one 2013
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy
LS Lamb, J Bowersock, A Dasgupta, GY Gillespie, Y Su, A Johnson, HT Spencer
PloS one 2013
Combining low-dose or metronomic chemotherapy with anticancer vaccines
HS Sow, SR Mattarollo
OncoImmunology 2013
Can Immunity to Breast Cancer Eliminate Residual Micrometastases?
ML Disis, SE Stanton
Clinical cancer research 2013
Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
D Alizadeh, M Trad, NT Hanke, CB Larmonier, N Janikashvili, B Bonnotte, E Katsanis, N Larmonier
Cancer research 2013
CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.
Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S, Théry C, Amigorena S, Combadière C
Neoplasia (New York, N.Y.) 2013
Doxorubicin sensitizes human tumor cells to NK and T cell-mediated killing by augmented TRAIL-receptor signaling
Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D\u2019arcy P, Zhivotovsky B, Childs R, Lundqvist A
International Journal of Cancer 2013
Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
R Ramakrishnan, DI Gabrilovich
Cancer Immunology, Immunotherapy 2013
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Fritzell S, Sandén E, Eberstål S, Visse E, Darabi A, Siesjö P
Cancer Immunology, Immunotherapy 2013
Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells
A Thakur, LG Lum, D Schalk, A Azmi, S Banerjee, FH Sarkar, R Mohommad
PloS one 2012
Treatment of a Solid Tumor Using Engineered Drug-Resistant Immunocompetent Cells and Cytotoxic Chemotherapy
A Dasgupta, JE Shields, HT Spencer
Human Gene Therapy 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
BG Till, MC Jensen, J Wang, X Qian, AK Gopal, DG Maloney, CG Lindgren, Y Lin, JM Pagel, LE Budde, A Raubitschek, SJ Forman, PD Greenberg, SR Riddell, OW Press
Blood 2012
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
ZC Ding, G Zhou
Clinical and Developmental Immunology 2012
Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
SR Slovin
Frontiers in Oncology 2012
Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing
SR Gameiro, JA Caballero, JW Hodge
Cancer Biotherapy and Radiopharmaceuticals 2012
The secret ally: immunostimulation by anticancer drugs
L Galluzzi, L Senovilla, L Zitvogel, G Kroemer
Nature Reviews Drug Discovery 2012
Exploiting evolution to treat drug resistance: Combination therapy and the double bind
D Basanta, RA Gatenby, AR Anderson
Molecular Pharmaceutics 2012
Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death
M Castells, B Thibault, JP Delord, B Couderc
International journal of molecular sciences 2012
STATing the importance of immune modulation by platinum chemotherapeutics
SV Hato, IJ de Vries, WJ Lesterhuis
OncoImmunology 2012
The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
JW Hodge, A Ardiani, B Farsaci, AR Kwilas, SR Gameiro
Seminars in Oncology 2012
Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism
H Kim, JI Sin
Human Vaccines & Immunotherapeutics 2012
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
R Ramakrishnan, C Huang, HI Cho, M Lloyd, J Johnson, X Ren, S Altiok, D Sullivan, J Weber, E Celis, DI Gabrilovich
Cancer research 2012
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
M Ciampricotti, CS Hau, CW Doornebal, J Jonkers, KE de Visser
Nature Medicine 2012
Platinum drugs break STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis, Cornelis J.A. Punt, Stanleyson V. Hato, Dagmar Eleveld-Trancikova, Bastiaan J.H. Jansen, Stefan Nierkens, Gerty Schreibelt, Annemiek De Boer, C.M.L. Van Herpen, Johannes H. Kaanders, Johan H.J.M. Van Krieken, Gosse Adema, Carl Figdor, I. Jolanda M. de Vries
Journal of Clinical Investigation 2011
Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy
E Proietti, F Moschella, I Capone, F Belardelli
Molecular Oncology 2011
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines
GM Weir, RS Liwski, M Mansour
Cancers 2011
Immune parameters affecting the efficacy of chemotherapeutic regimens
L Zitvogel, O Kepp, G Kroemer
Nature Reviews Clinical Oncology 2011
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses
SR Gameiro, JA Caballero, JP Higgins, D Apelian, JW Hodge
Cancer Immunology, Immunotherapy 2011
Cancer immunotherapy – revisited
WJ Lesterhuis, JB Haanen, CJ Punt
Nature Reviews Drug Discovery 2011
Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies
R Vermeij, N Leffers, SH van der Burg, CJ Melief, T Daemen, HW Nijman
Journal of Biomedicine and Biotechnology 2011
CD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma
KU Sorenmo, E Krick, CM Coughlin, B Overley, TP Gregor, RH Vonderheide, NJ Mason
PloS one 2011
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June
Science Translational Medicine 2011
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
A Sistigu, S Viaud, N Chaput, L Bracci, E Proietti, L Zitvogel
Seminars in Immunopathology 2011
Immune microenvironments in solid tumors: new targets for therapy
SL Shiao, AP Ganesan, HS Rugo, LM Coussens
Genes & development 2011
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
C Jochems, J Schlom
Experimental biology and medicine (Maywood, N.J.) 2011
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
DL Porter, BL Levine, M Kalos, A Bagg, CH June
The New England journal of medicine 2011
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
NR West, K Milne, PT Truong, N Macpherson, BH Nelson, PH Watson
Breast Cancer Research 2011
Current Immunotherapeutic Approaches in Pancreatic Cancer
S Koido, S Homma, A Takahara, Y Namiki, S Tsukinaga, J Mitobe, S Odahara, T Yukawa, H Matsudaira, K Nagatsuma, K Uchiyama, K Satoh, M Ito, H Komita, H Arakawa, T Ohkusa, J Gong, H Tajiri
Clinical and Developmental Immunology 2011
Novel antibody-based proteins for cancer immunotherapy
J Fuenmayor, RF Montaño
Cancers 2011
[Researche advances on CIK cells and their clinical use in lung cancer]
Hu Luo, Xiangdong Zhou
Zhongguo fei ai za zhi = Chinese journal of lung cancer 2011
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing
Bao L, Dunham K, Lucas K
Cancer Immunology, Immunotherapy 2011
Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?
Dunning NL, Laversin SA, Miles AK, Rees RC
Cancer Immunology, Immunotherapy 2011
Immunotherapy eradicates metastases with reversible defects in MHC class I expression
Garrido C, Romero I, Berruguilla E, Cancela B, Algarra I, Collado A, García-Lora A, Garrido F
Cancer Immunology, Immunotherapy 2011
Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms
ZG Fridlender, J Sun, S Singhal, V Kapoor, G Cheng, E Suzuki, SM Albelda
Molecular Therapy 2010
Advances in Cellular Therapy for the Treatment of Thyroid Cancer
C Papewalis, M Ehlers, M Schott
Journal of Oncology 2010
Therapeutic Cancer Vaccines in Combination with Conventional Therapy
MH Andersen, N Junker, E Ellebaek, IM Svane, PT Straten
Journal of Biomedicine and Biotechnology 2010
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells
TJ Haggerty, IS Dunn, LB Rose, EE Newton, S Martin, JL Riley, JT Kurnick
Cancer Immunology, Immunotherapy 2010
Targeting dendritic cell metabolism in cancer
L Zitvogel, G Kroemer
Nature Medicine 2010
Chemotherapy: Conventional chemotherapy boosts the effect of cancer vaccines
L Richards
Nature Reviews Clinical Oncology 2010
Chemoimmunotherapy:
LA Emens
The Cancer Journal 2010
The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.
Arlen M, Arlen P, Tsang A, Wang X, Gupta R
Journal of Cancer 2010
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.
Straten Pt, Andersen MH
Oncotarget 2010
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA
Cancer Immunology, Immunotherapy 2010
Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer
Ramakrishnan R, Gabrilovich DI
Cancer Immunology, Immunotherapy 2010
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
thor Straten P, Andersen MH
Oncotarget 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 … 9 10 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 policy sources
Posted by 2 X users
Referenced in 7 patents
Highlighted by 1 platforms
267 readers on Mendeley
1 readers on CiteULike
See more details